

Satellite symposium: The coming of age for CDK 4/6 inhibitors

ecancer.org

Silver Hall, Square Brussels Meeting Centre
13:15 - 14:15, Friday 5 May

Dear colleague

On behalf of ecancer, I am delighted to invite you to a very special educational event on Friday 5 May that will outline the latest research, data and treatment options for metastatic breast cancer patients.

The session will be highly interactive and will provide you with the latest emerging evidence for the optimal integration of new therapies into treatment plans for breast cancer patients, which can be directly applied in clinical practice.

We look forward to welcoming you to this symposium.



Giuseppe Curigiano,

Senior Deputy Director, Division of
Medical Oncology, European Institute
of Oncology, Milan, Italy



Gordon McVie,

Visiting Professor in Cancer Studies
at Kings College London,
Founding Editor ecancer

Supported by a grant from Pfizer Inc.

Speakers

Nicholas Turner,

The Royal Marsden, London, UK

Sibylle Loibl,

German Breast Group (GBG),
Frankfurt, Germany

Agenda

- Current clinical data for CDK 4/6 inhibitors in breast cancer
- Ongoing investigations and future applications
- Review of clinical cases